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BRCA1/2 mutations predispose to early-onset breast cancer, especially after oral contraceptive (OC) use and pregnancy. However,
the majority of breast cancers might be due to more prevalent low-penetrance genes, which may also modify the risk in BRCA
mutation carriers. The absence of the IGF1 19-repeat allele has been associated with high insulin-like growth factor-1 (IGF-1) levels
during OC use. High IGF-1 levels are linked to early-onset breast cancer and larger breast volumes in the general population. The goal
of this study was to elucidate the relationships between IGF1 genotype, early-onset breast cancer, breast volume, circulating IGF-1
levels and OC use in a prospective cohort of 258 healthy women p40 years old from high-risk breast cancer families. All women
completed a questionnaire including information on reproductive factors and OC use. We measured the height, weight, breast
volumes and plasma IGF-1 levels. IGF-1 levels were similar among parous and nulliparous women not using OCs. In all, 13% had no
IGF1 19-repeat allele. There was an interaction between IGF1 genotype and OC use on IGF-1 levels (P¼0.026) in nulliparous
women and another interaction between IGF1 genotype and parity on breast volume (P¼0.01). Absence of the 19-repeat allele was
associated with high IGF-1 levels in nulliparous OC users and with larger breast volumes in parous women and OC users. Incident
breast cancers were also more common in women without the 19-repeat allele (log rank P¼0.002). Our results suggest that lack of
the IGF1 19-repeat allele modifies IGF-1 levels, breast volume and possibly early-onset breast cancer risk after hormone exposure in
young high-risk women.
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Early-onset breast cancer is a devastating disease for young women
and their families. Several genes predisposing to early-onset breast
cancer have been identified, most notably BRCA1 and BRCA2.
Carriers of the BRCA1 and BRCA2 mutations face a lifetime risk of
breast cancer of over 80% (Easton et al, 1995; Tonin et al, 1995;
Ford et al, 1998), although lower numbers have been reported
(Streuwing et al, 1997; Antoniou et al, 2003). BRCA1 and BRCA2
promote differentiation and counteract proliferation during
pregnancy and periods of concomitant oestrogen and progesterone
administration (Marquis et al, 1995; Rajan et al, 1996), such as
during oral contraceptive (OC) use. Both pregnancy and OC use
increase the risk of breast cancer among carriers of BRCA1 and
BRCA2 mutations (Jernstro ¨m et al, 1999; Narod et al, 2002). In and
of itself, teenage OC use has been associated with a small increase
in early-onset breast cancer during use and up to 10 years
following cessation of use in the general population (Collaborative
Group on Hormonal Factors in Breast Cancer, 1996). Neither the
presence of the BRCA mutations alone, nor the use of OCs, nor the
combination of the two are sufficient to predict which women will
develop early-onset breast cancer. It is likely that more prevalent
low-penetrance genes in combination with environmental expo-
sures modify breast cancer risk in BRCA1 and BRCA2 mutation
carriers as well as contribute to breast cancer risk among women
in the general population.
Insulin-like growth factor-1 (IGF-1) is essential for the normal
development of the female breast both during puberty and
pregnancy, along with various hormones, including oestrogen,
progesterone and prolactin (Dickson, 1996). The IGF system plays
a key role in regulating cell proliferation and apoptosis (Stewart
and Rotwein, 1996). Insulin-like growth factor-1 levels inscribe a
gene expression profile for angiogenic factors and cancer
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sprogression in breast epithelial cells (Oh et al, 2002). In the general
population, high IGF-1 levels have been linked to premenopausal
(Hankinson et al, 1998), but not to postmenopausal, breast cancer
(Jernstro ¨m and Barrett-Connor, 1999). Parous women in the
general population have lower IGF-1 levels than nulliparous
women (Holmes et al, 2002); after pregnancy, the risk of breast
cancer is transiently increased, and is then lower for a period
extending into the postmenopausal years (Beral and Reeves, 1993).
It is possible that the decrease in IGF-1 levels in parous women
accounts partially for the protective effect of parity against breast
cancer.
The levels of circulating IGF-1 have also been linked to breast
volume. High IGF-1 levels are associated with larger breast
volumes in nulliparous women who are not using OCs (Jernstro ¨m
and Olsson, 1997). It has been observed that among young women
who underwent hormonal breast augmentation with oestrogen,
only those who responded with a significant increase in IGF-1
levels had substantial increases in breast volume (Hartmann et al,
1998). Increased levels of IGF-1 are also linked to increased breast
density in premenopausal, but not postmenopausal, women (Byrne
et al, 2000). Increased breast density after hormonal exposure is
associated with increased risk of subsequent breast cancer (Boyd
et al, 2001) and it has been hypothesised that increased breast
volume during hormonal exposure may be a surrogate marker for
increased breast cancer risk (Olsson, 1990).
The promoter region of the IGF1 gene contains a CA-repeat
sequence, which ranges from 12 to 23 repeats (Rosen et al, 1998).
Most white women have at least one copy of the 19-repeat allele
(Jernstro ¨m et al, 2001b), but the frequency of the 19-repeat allele
varies between ethnic groups (Jernstro ¨m et al, 2001a). Insulin-like
growth factor-1 levels decrease in most white OC users compared
with white non-users (Jernstro ¨m and Olsson, 1994). However, the
absence of the common 19-repeat allele in the IGF1 gene is
associated with high IGF-1 levels during OC use in nulliparous
women (Jernstro ¨m et al, 2001a,b). The risk of early-onset breast
cancer after teenage OC use varies considerably between ethnic
groups (Marcus et al, 1999), and appears to correlate with the
relative frequencies of the absence of the 19-repeat allele among
these ethnic groups (Jernstro ¨m et al, 2001a). In addition, the
absence of the 19-repeat allele appears to mitigate the normal age-
related decline in IGF-1 levels (Rietveld et al, 2003). To our
knowledge, no one has studied the interaction between the absence
of the 19-repeat allele and parity on IGF-1 levels and subsequent
breast cancer risk.
We have hypothesised that the elevation in IGF-1 levels, brought
on by pregnancy or exogenous hormones (in particular teenage OC
use) in the context of an absent 19-repeat allele, may play an
important role in the pathogenesis of early-onset breast cancer and
lead to an increase in breast volume (Figure 1). According to this
hypothesis, the absence of the 19-repeat allele in and of itself may
be a marker of increased early-onset breast cancer risk after
pregnancy and OC use, and may be especially useful among BRCA
mutation carriers where early-onset breast cancer is common. The
aims of this study were to elucidate the relationships between IGF1
genotype, early-onset breast cancer, breast volume, circulating
IGF-1 levels, pregnancy and OC use in a prospective cohort of
healthy premenopausal women from high-risk breast cancer
families.
MATERIALS AND METHODS
Study population
To be eligible for participation, the women had to belong to high-
risk breast cancer families and be either a known BRCA1 or BRCA2
mutation carrier or a first- or second-degree relative of a breast
cancer case or known male or female BRCA1 or BRCA2 mutation
carrier with or without breast cancer. We considered a family to be
at high risk for breast cancer if three women had been diagnosed
with breast cancer and at least one of these was below age 50 years
at diagnosis, or two women and at least one was below age 40 years
at diagnosis or one woman was diagnosed with breast cancer prior
to age 30 years. Participants had to be 40 years of age or younger
and menstruating. Exclusion criteria were a previous prophylactic
mastectomy or a bilateral oophorectomy or any type of cancer
diagnosis at the time of enrolment between 1996 and 2002. In all,
258 young women from breast cancer high-risk families volun-
teered to participate in this study. Potential participants were
identified from charts and pedigrees from the Lund Oncogenetic
Clinic. Individuals who themselves had been to the clinic were
contacted, first by a letter including brief information on the study,
then by phone. In cases where the index individuals were not
eligible, they were asked whether they were willing to inform
relatives of the study and then inform us as to whether we might
contact their relatives directly. The ethical committee at the Lund
University approved the study.
Data collection
A letter including an extensive epidemiologic questionnaire and a
written consent form was mailed to women who verbally agreed to
participate. The questionnaire included questions on reproductive
factors, such as age at menarche, menstrual cycle length, age at
full-term pregnancies, duration of breast-feeding for each child,
the use of OCs and other medications, smoking habits, diet, coffee
consumption, physical exercise, etc. Other questions included the
number of older siblings, the age of the mother and the age of the
father of the woman when she was born. A trained research nurse
collected blood samples and body measurements during menstrual
cycle days 5–10 and again 5–10 days before the predicted onset of
the following menstrual period. All women were asked to call back
with the date of the first day of their next menstrual period. Body
measurements included height, weight, waist and hip circumfer-
ences, and breast volume. Breast volumes were measured while the
woman was on her hands and knees with the breasts hanging
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Figure 1 The figure shows the proposed mechanisms by which we
hypothesise that absence of the IGF1 19-repeat allele in combination with
hormone exposure would increase the breast volume and the risk of early-
onset breast cancer. References to the steps that have been previously
explored are indicted. The risk of early-onset breast cancer after hormone
exposure may be partially modified through the IGF-1 pathway.
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sdown. The volume was approximated to a pyramid (base
area height/3). Total breast volume, that is, the sum of the right
and left breast volumes, was calculated for each visit. Initially, we
only measured one of the breasts and for the first woman total
breast volume is missing for both visits and for the next three
women total breast volume is missing for one visit. The plasma
and blood cells were separated and frozen at minus 701C at our
laboratory at the Department of Oncology, Lund.
Mutation testing
Mutation testing of the BRCA1 and BRCA2 genes was not
performed as part of this study. BRCA1 and BRCA2 mutation
testing is offered at the Oncogenetic clinic at the Department of
Oncology in Lund if an individual has at least three first-degree
relatives with breast cancer and one diagnosed before age 50; two
first-degree relatives with breast cancer and one diagnosed before
age 40; or one first-degree relative with breast cancer diagnosed
before age 30. Women are usually not offered testing before age 25
years. BRCA gene mutation carriers included only those with
confirmed deleterious alterations, that is, nonsense or frameshift
indel mutations that cause protein truncation, or known disease-
associated missense mutations.
The participating women were classified into eight different
categories:
1. BRCA1 mutation carriers (n¼20);
2. non-BRCA1 mutation carriers from a family with a known
BRCA1 mutation (n¼47);
3. untested women from a family with a known BRCA1 mutation
(n¼17);
4. BRCA2 mutation carriers (n¼7);
5. non-BRCA2 mutation carriers from a family with a known
BRCA2 mutation (n¼6);
6. untested women from a family with a known BRCA2 mutation
(n¼2);
7. women belonging to a family where no BRCA1 or BRCA2
mutations could be detected, that is, members of a ‘non-
BRCA1/2 family’ (n¼113);
8. women from untested high-risk families (n¼46). These
families were untested for various reasons, for example, all
breast and ovarian cancer cases were deceased or refused
testing.
Follow-up
Women were followed until the development of a first breast
cancer according to the regional cancer registries, until the date of
a self-reported prophylactic mastectomy or until March 31, 2003,
whichever came first. No woman had undergone a prophylactic
oophorectomy before undergoing a prophylactic mastectomy. The
report rate of cancer diagnoses to the Swedish cancer registries is
close to a 100%. The clinical follow-up of high-risk women
includes annual mammograms, ultrasounds and MRIs of the
breasts in addition to a physical examination and annual follow-
ups of the ovaries by ultrasound, CA-125 and a gynecological
examination.
DNA testing
Genomic DNA was extracted from 300ml peripheral blood using
Wizard, Genomic DNA Purification Kit, Promega. The polymorph-
ism in the IGF1 gene is a tandem dinucleotide repeat, ranging in
size from 12 to 23 repeats. PCR primers 50-GCTAGCCAGCTGG
TGTTATT and 50-GTTTCTTACCACTCTGGGAGAAGGGTA were
used, where the forward primer was fluorescently labelled with
FAM (MWG-Biotech AG).
PCR was performed in 15-ml reactions using 25ng DNA, 0.4mM
of each primer, 0.1mM of each deoxynucleotide (Amersham
Biosciences, Buckinghamshire, UK), 5% DMSO (Sigma, St Louis,
MO, USA), 2.5mM MgCl2 (Applied Biosystems, Foster City, CA,
USA), 1  PCR Gold buffer (Applied Biosystems) and 1U
AmpliTaq Gold (Applied Biosystems).
The PCR product was analysed in an ABI3100 Genetic Analyzer
(Applied Biosystems) and the results were evaluated using
Genescan software. The number of repeats was determined by
sequencing samples of varying sizes (Big Dye, Terminator Cycle
Sequencing, Applied Biosystems) and using them as standards in
fragment size analysis.
Insulin-like growth factor-1 analyses
Insulin-like growth factor-1 was analysed in EDTA plasma using
the radio-immuno assay (RIA) method at the Endocrinological
laboratory at the Karolinska Hospital, Stockholm, Sweden, as
previously described by Bang et al (1991). Acid ethanol extraction
followed by cryo-precipitation was used to separate insulin-like
binding proteins (IGFBPs) from IGF-1 and decrease the inter-
ference of IGFBPs in the IGF-1 RIA. Recombinant human IGF-1
(Kabi-Pharmacia, Stockholm, Sweden) was used as standard. The
international IGF-1 standard was delivered by the National
Institute of Biological Standards and Control, London, Great
Britain. The intra-assay variation was 4% and the inter-assay
variation was 11%. The limit of detection was 6mgl
 1.
Data analyses
The statistical software SPSS 10.0.7 was used for all statistical
analyses. Breast volumes and body weights were not normally
distributed and the values were transformed using the natural
logarithm to obtain better distribution. Spearman rank correlation
coefficients were used for correlations. Mann–Whitney U-test was
used to compare the body weight between parous and nulliparous
women. Chi-square was used to compare the frequency of the
absence of IGF1 19-repeat allele between known BRCA1 mutation
carriers and other women. Multivariate linear regression was used
to compare circulating IGF-1 levels in relation to genotype, parity
and use of hormonal contraceptives. A log-rank test was used to
analyse the risk of breast cancer in relation to IGF1 genotype. Cox
regression was used to analyse the hazard of developing breast
cancer in relation to IGF1 genotype adjusting for other factors. As
the study was based on a priori hypotheses, that is, that the IGF1
genotype was associated with an idiosyncratic response to
hormone exposure in young women (Jernstro ¨m et al, 2001a,b),
no adjustment for multiple testing was required. We calculated the
sample size needed to detect a minimum of 20% difference (7)i n
breast volume between nulliparous and parous women with and
without the 19-repeat allele, with 80% power and an alpha value of
0.05, assuming a mean breast volume of 900cm
3 and a standard
error of 250, and that 50% of the women were parous and equally
distributed between the two genotypes. If the frequency of the
absence of the 19-repeat allele were 10% we would need 250
women ,and if the frequency were 15% we would need 177 women.
A P-value of o0.05 was taken to be significant. All P-values were
two-sided.
RESULTS
The characteristics of the 258 women at baseline are described in
Table 1. Six women had developed cancer during follow-up. There
were no significant differences in reproductive factors, body sizes
or use of hormonal contraceptives between women with and
without breast cancer at follow-up. In all, 254 women agreed to
undergo genotyping of the IGF1 gene. The BRCA1 and BRCA2
IGF1 genotype linked to IGF-1 levels, breast volume, cancer risk
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smutation status of the women with and without breast cancer is
described in Table 2; four cases were known BRCA1 mutation
carriers and two cases came from untested families and have not
undergone testing themselves. The allele frequency distribution of
the IGF1 gene is described in Table 3; absence of the IGF1 19-
repeat allele was more common among the women with breast
cancer (66.7%) than among the women without breast cancer
(11.7%). Total breast volume measurements, taken 5–10 days
before the predicted onset of the next menstrual period, were
available for 240 women who were not currently breast-feeding
and who had not undergone previous breast augmentation or
reduction surgeries.
Breast volume was strongly correlated with body weight
(rs¼0.68; Po0.001) and the waist-to-hip ratio (rs¼0.50;
Po0.001), but not with height (rs¼0.15; P¼0.08). Parous women
were on average 5.4kg heavier than nulliparous women
(P¼0.001). The weight-adjusted breast volumes in nulliparous
and parous women depended on the IGF1 genotype and current
hormonal contraceptive status. In all, 87% of the women carried at
least one IGF1 19-repeat allele. Women who lacked the IGF1 19-
repeat allele were nonsignificantly lighter than women with at least
one 19-repeat allele (P¼0.15, adjusted for parity), while no effect
on height was seen. There was a strong interaction between parity
and IGF1 genotype on breast volume (P¼0.01). We therefore
stratified the women depending on the absence or presence of the
19-repeat allele. Among the 209 women with at least one 19-repeat
allele, the weight-adjusted breast volume was significantly smaller
in parous women compared with nulliparous women (P¼0.02)
and nonsignificantly smaller in current oral or hormonal contra-
ceptive users (P¼0.06). Conversely, among the 30 women with no
19-repeat allele, the weight-adjusted breast volumes were non-
significantly larger in parous than in nulliparous (P¼0.06), and
also nonsignificantly larger in current OC users (P¼0.12).
We collected plasma for studying circulating levels of IGF-1 at
two time-points during the menstrual cycle from each woman, 5–
10 days after onset of the menstrual period and again 5–10 days
Table 1 Characteristics of women with and without breast cancer at follow-up
No breast cancer (n¼258) Breast cancer (n¼252) No breast cancer vs breast cancer (n¼6)
All women Mean (7s.d.) Mean (7s.d.) Mean (7s.d.) P-value
Age at baseline 29.1 (76.3) 29.1 (76.4) 33.3 (76.3) 0.10
Age at menarche 12.8 (71.3) 12.8 (71.3) 13.2 (70.4) 0.06
Parous at baseline 126/258 (49%) 121/252 (48%) 5/6 (83%) 0.08
Age at first birth 24.8 (74.0) 24.7 (74.0) 26.0 (73.7) 0.48
Smoker at baseline 58/257 (23%) 55/251 (22%) 3/6 (50%) 0.10
Oral contraceptives, ever 237/258 (92%) 231/252 (92%) 6/6 (100%) 0.46
Start age (years) 17.2 (72.7) 17.2 (72.7) 16.8 (71.3) 0.74
Hormonal contraception, baseline
OC 100/252 (39%) 99/252 (39%) 1/6 (17%)
Levonova prog IUD 6/258 (2.3%) 6/252 (2.4%) 0/6 (0%)
Norplant 2/258 (0.8%) 2/252 (0.8%) 0/6 (0%)
Implanon 1/258 (0.4%) 1/252 (0.4%) 0/6 (0%)
Height, cm 168 (76.0) 168 (76.0) 168 (74.9) 0.95
Waist-to-hip ratio
a 0.77 (70.06) 0.77 (70.06) 0.79 (70.04) 0.33
Weight (kg)
a,b 66.1 66.1 68.3 0.43
Breast volume (cm
3)
a,b 762 759 915 0.53
aThe values for weight, waist-to-hip ratio and breast volume were measured 5–10 days prior to the predicted onset of the next menstrual period.
bThe values for weight and
breast volume were not normally distributed and the geometric means are presented.
Table 2 BRCA1 and BRCA2 mutation status of the cases and controls
All women
(n¼258)
Controls
(n¼252) Cases (n¼6)
No. (%) No. (%) No.(%)
BRCA1
Positive 20 (7.8%) 16 (6.3%) 4 (80.0%)
Negative 47 (18.2%) 47 (18.7%) —
Untested 17 (6.6%) 17 (6.7%) —
BRCA2
Positive 7 (2.7%) 7 (2.8%) —
Negative 6 (2.3%) 6 (2.4%) —
Untested 2 (0.8%) 2 (0.8%) —
Non-BRCA1/2 family 113 (43.8%) 113 (44.8%) —
Untested family 46 (17.8%) 44 (17.5%) 2 (20.0%)
We considered women who belong to known BRCA1 or BRCA2 families to be non-
mutation carriers if they tested negative themselves or if their parent tested negative
for the known mutation in the family. Untested women from BRCA1 and BRCA2
families have between 25 and 50% risk of carrying the mutation segregating in their
respective families.
Table 3 Allele frequency distribution of polymorphic genetic variants by
breast cancer status at follow-up
IGF1 genotype
All women
(n¼254)
No breast
cancer (n¼248)
Breast cancer
(n¼6)
(VNTR) No. (%) No. (%) No. (%)
12 3 (0.6%) 2 (0.4%) 1 (8.3%)
13 — — —
14 — — —
15 — — —
16 — — —
17 8 (1.6%) 8 (1.6%) —
18 32 (6.3%) 32 (6.5%) —
19 333 (65.6%) 330 (66.5%) 3 (25.0%)
20 91(17.9%) 87 (17.5%) 4 (33.3%)
21 35 (6.9%) 32 (6.5%) 3 (25.0%)
22 6 (1.2%) 5 (1.0%) 1 (8.3%)
IGF1 19-repeat allele
Absent 33 (13.0%) 29 (11.7%) 4 (66.7%)
Present 221 (87.0%) 219 (88.3%) 2 (33.3%)
Genotype was missing for four women without breast cancer.
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sprior to the predicted onset of the next menstrual period, that is,
during menstrual cycle days 18–23 in most women. Insulin-like
growth factor-1 levels were missing during cycle days 5–10 for one
woman. For several of the hormonal contraceptive users, the
samples obtained during cycle days 5–10 were collected during
their pill-free week. However, the second samples were obtained
during cycle days 18–23, when the women were taking active pills.
We excluded the five women who were currently breast-feeding at
the time of blood collection from the analyses.
Age was correlated with IGF-1 levels both during cycle days 5–
10 (rs¼0.51; Po0.001) and during cycle days 18–23 (rs¼0.37;
Po0.001). There were no major differences in age decline in
circulating IGF-1 levels in the samples collected during cycle days
5–10 between women with or without the IGF-1 19-repeat allele
(rs¼0.50 and 0.52, respectively), while the age decline in the
samples obtained during cycle days 18–23 was larger among
women with than without the 19-repeat allele (rs¼0.39 and 0.30,
respectively).
Parity and current hormonal contraception had no significant
impact on the age-adjusted IGF-1 levels obtained during cycle days
5–10 (P¼0.39 and 0.67, respectively). During cycle days 18–23,
there was an interaction between parity and current hormonal
contraception on IGF-1 levels (P¼0.05). The age-adjusted IGF-1
levels during cycle days 18–23 were similar among parous and
nulliparous women not using hormonal contraception (P¼0.49,
Figure 2). Current hormonal contraception was strongly associated
with lower age-adjusted IGF-1 levels (P¼0.00003) among nulli-
parous women, while no such effect was seen among parous
women (P¼0.35). Among hormonal contraceptive users, parous
women had nonsignificantly higher circulating IGF-1 levels
compared with nulliparous hormonal contraceptive users
(P¼0.11). The results remained essentially the same if women
who were using other types of hormonal contraception than
combined OCs were excluded.
The IGF1 genotype modified the effect of hormonal contra-
ceptives on the IGF-1 levels during cycle days 18–23 among
nulliparous women, and there was a significant interaction
between IGF1 genotype and hormonal contraception on IGF-1
levels (P¼0.026, Figure 3). Nulliparous hormonal contraceptive
users with at least one copy of the 19-repeat allele had significantly
lower age-adjusted IGF-1 levels than non-users (P¼7 10
 6), but
not hormonal contraceptive users lacking the 19-repeat allele
(P¼0.81), confirming previous studies of an idiosyncratic
response in circulating IGF-1 levels to hormonal contraception
among nulliparous women lacking the IGF1 19-repeat allele. The
results remained essentially the same for nulliparous women if
women who were using hormonal contraception other than
combined OCs were excluded. Among parous women, no
significant effect on age-adjusted IGF-1 levels from hormonal
contraceptive use was seen, independent of IGF1 genotype. The
results remained essentially the same if women who were using
hormonal contraception other than combined OCs were excluded.
The IGF1 genotype did not significantly modify the effect of
pregnancy on circulating IGF-1 levels among women not using
hormonal contraception and who were not currently breast-
feeding. No significant difference between parous and nulliparous
women was seen irrespective of the absence or presence of the 19-
repeat allele.
To date, six women have been diagnosed with breast cancer,
three with bilateral disease. The median follow-up time of the
cohort was 1.4 years (range 0.07–6.93 years). Two of the breast
cancers were diagnosed at the time of prophylactic mastectomy. In
all, 14 other women reported having undergone prophylactic
mastectomies after inclusion in this study, but no cancers were
detected at the time of surgery. Four cases were known BRCA1
mutation carriers and two cases belonged to untested families and
have chosen to not undergo testing themselves after their cancer
diagnoses. The median age at diagnosis was 38.5 years (range 28–
44 years). All cases had started OC use during their teenage years
and only one had never given birth. Absence of the IGF1 19-repeat
allele was associated with breast cancer during follow-up (log-rank
P¼0.002, Figure 4). We then restricted the analysis to include only
women who had been exposed to OCs during their teenage years.
The age-adjusted hazard ratio for women who had started OC use
before age 20 years and who had no copy of the 19-repeat allele
compared to women with at least one copy of the 19-repeat allele
was 10.2 (95% CI 1.85–56.7; P¼0.007). In the second model, we
included only parous women. The age-adjusted hazard ratio for
parous women lacking the 19-repeat allele was 6.62 (1.05–41.67;
P¼0.04) compared with parous women with at least one copy of
the 19-repeat allele.
A large proportion of the women are still untested for BRCA1
and BRCA2 mutations, mostly because of their young age or
because no affected family member could be tested. Absence of the
19-repeat allele of the IGF1 gene was more often found in known
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Figure 2 (A, B) show that there were no significant differences in
median IGF-1 levels between parous and nulliparous women not currently
using any hormonal contraception in the samples obtained during cycle
days 5–10 (P¼0.57) or in the samples obtained during cycle days 18–23,
that is, 5–10 days prior to the predicted onset of the next menstrual
period (P¼0.49). The horizontal line in the box indicates the median value,
the box boundaries the 25th and 75th percentiles, and the capped bars the
10th and the 90th percentiles. The number of women in each group is
indicated. Circles indicate outliers with values between 1.5 and 3 box
lengths from the upper or lower edge of the box. Asterisks indicate
extreme outliers with values more than 3 box lengths from the upper or
lower edge of the box. The box length is the interquartile range.
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sBRCA1 mutation carriers than in other women (30.0 vs 11.5%;
P¼0.018) and the two variables could therefore not be examined
in the same model. Our data suggest that BRCA1 mutation carriers
who also lack the IGF1 19-repeat allele may be at a higher risk for
early-onset breast cancer than BRCA1 mutation carriers with
presence of the 19-repeat allele. Among the 20 women with known
BRCA1 mutations, six were lacking the 19-repeat allele. Of these six
women, two have undergone prophylactic mastectomy, three have
been diagnosed with breast cancer and one is still healthy. Among
the 14 women with at least one copy of the 19-repeat allele, six have
undergone prophylactic mastectomy, one has been diagnosed with
breast cancer and seven are still healthy.
As an additional control group, we also performed IGF1
genotyping on 86 women with available DNA from the South
Swedish BRCA1 mutation families who did not carry the mutation in
their respective families and who did not have breast cancer at the
time of testing. These women were between 20 and 91 years old at the
time of testing. Three of the 32 women (9.4%) who were 40 years or
younger at the time of testing lacked the 19-repeat allele, and two of
the 54 women (3.7%) who were 41 years or older at the time of
BRCA1 mutation testing lacked the 19-repeat allele. When this
additional control group and the 45 BRCA1 n e g a t i v ew o m e ni nt h e
present study were considered together, the frequency of the absence
of the 19-repeat allele was 8.4% among all BRCA1-negative women in
the South Swedish region with available DNA. For women aged 40
years or younger at testing, the frequency was 11.7%.
DISCUSSION
The main findings of this study were that the absence of the
common IGF1 19-repeat allele was associated with larger breast
volumes in parous women and in hormonal contraceptive users,
after adjustment for body weight, and secondly that parity was not
associated with a decrease in circulating IGF-1 levels contrary to
the report based on women in the general population (Holmes et al,
2002). We also confirmed our previous reports based on healthy
nulliparous Canadian women (Jernstro ¨m et al, 2001a,b) that the
absence of the IGF1 19-repeat allele was associated with an
idiosyncratic response on circulating IGF-1 levels to hormonal
contraception among nulliparous women. Our preliminary ana-
lyses suggest an increased risk of early-onset breast cancer risk
after hormonal exposure, such as teenage hormonal contraception
or a pregnancy, in women lacking the IGF1 19-repeat allele.
High IGF-1 levels are associated with increased risk for
premenopausal breast cancer (Hankinson et al, 1998). They
inscribe a gene expression profile for angiogenic factors and
cancer progression in breast epithelial cells (Oh et al, 2002) and
accelerate the progression of precancerous changes to invasive
lesions. Thus, on the basis of epidemiological and experimental
studies, a decrease in circulating IGF-1 levels may help reduce the
risk of breast cancer, especially among members of high-risk
families (Furstenberger and Senn, 2002). As for postmenopausal
breast cancer, neither the levels of circulating IGF-1 (Jernstro ¨m
and Barrett-Connor, 1999) nor the IGF1 genotype appear to affect
the risk (Missmer et al, 2002; DeLellis et al, 2003). The frequency of
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Figure 3 (A, B) show that the IGF1 genotype modified the effect of
hormonal contraceptives on the IGF-1 levels in nulliparous women. The
interaction between IGF-1 genotype and hormonal contraception was
nonsignificant during cycle days 5–10 (P¼0.13) and significant during cycle
days 18–23, that is, 5–10 days prior to the predicted onset of the next
menstrual period (P¼0.026). The horizontal line in the box indicates the
median value, the box boundaries the 25th and 75th percentiles, and the
capped bars the 10th and the 90th percentiles. The number of women in
each group is indicated. Circles indicate outliers with values between 1.5
and 3 box lengths from the upper or lower edge of the box. Asterisks
indicate extreme outliers with values more than 3 box lengths from the
upper or lower edge of the box. The box length is the interquartile range.
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Figure 4 The figure shows the cumulative breast-cancer-free survival
after study entry in women with and without the IGF1 19-repeat allele. The
difference between the two groups was significant (log-rank P¼0.002).
Follow-up was censored at the time of prophylactic mastectomy without
detection of breast cancer or on March 31, 2003. Please note the broken
Y-axis. The number of women at each time point is indicated.
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sthe absence of the 19-repeat allele varies greatly between ethnic
groups and is highest among African-American women (Jernstro ¨m
et al, 2001a; DeLellis et al, 2003). Missmer et al (2002) found no
interaction between the absence of the 19-repeat allele and overall
breast cancer risk. However, they did not match their cases and
controls for ethnic background, which may have affected their
results. They also did not find any association between this
genotype combined with ever OC use and breast cancer, but they
did not examine the effect of teenage OC use, and the women
included in that study were older than in our study, range 43–69
years, and were thus unlikely to be diagnosed with OC-associated
early-onset breast cancer. The effect of OCs on breast cancer is
generally thought to be limited to early-onset breast cancer, for
example, prior to age 35 or 40 years of age (Collaborative Group on
Hormonal Factors in Breast Cancer, 1996). Neither the study by
Missmer et al (2002) nor the study by DeLellis et al (2003)
examined the possibility that the absence of the IGF1 19-repeat
allele is a latent polymorphism that only gives rise to an increased
risk of early-onset breast cancer in combination with teenage OC
use, and possibly pregnancy, but does not affect late-onset breast
cancer. A recent case–control study of breast cancer in twins
suggested that the breast tissue in women with a certain genotype
might show an unusual sensitivity to pubertal hormones and an
absence of linkage to hormonal milestones later in life (Hamilton
and Mack, 2003). Teenage OC use has been associated with a
several fold increased risk of early-onset breast cancer compared
with use commenced after age 20 years (Olsson et al, 1989).
Twin studies (Kao et al, 1994; Harrela et al, 1996) have shown
that about 50% of the inter-individual variability in circulating
IGF-1 levels is genetically determined. The IGF1 polymorphism is
located in the promoter region of the IGF1 gene (Rosen et al,
1998). This microsatellite polymorphism is located one kilobase
upstream from the IGF1 transcription start site (Rotwein et al,
1986; Weber and May, 1989) and contains specific regulatory
elements (McCarthy et al, 1997). In vitro studies of rat osteoblasts
have shown a 100–300-fold difference in their ability to suppress
the stimulatory effect of prostaglandin E2 in response to 17-alpha
and 17-beta estradiol when they bind to the oestrogen response
elements within the IGF1 promoter region (McCarthy et al, 1997).
The IGF1 polymorphism appeared to have no impact on IGF-1
levels in nulliparous women who are not using OCs, while women
with no copies of the IGF1 19-repeat allele demonstrated high IGF-
1 levels during OC use (Jernstro ¨m et al, 2001a,b). The present
study confirmed our previous findings that hormonal contra-
ceptives were associated with decreased circulating IGF-1 levels
only among nulliparous women with presence of the 19-repeat
allele. The difference in IGF-1 levels among OC users with and
without the 19-repeat allele suggests that this allele may be
associated with a conformational change in the region of the IGF-1
promoter, possibly involving the oestrogen response element.
However, we did not observe the same effect among parous women
in the current study.
The women included in our cohort were selected on the basis of
the fact that they belonged to high-risk breast cancer families with
several cases of breast or ovarian cancer. The penetrance of the
BRCA1 and BRCA2 genes varies according to the selection of the
families (Easton et al, 1995; Tonin et al, 1995; Antoniou et al,
2003). It is therefore likely that other modifying genetic variants
segregate at a high frequency in the current cohort, because it is
based on a selection of volunteers from families with multiple
cases of cancers. The percentage of women without a copy of the
19-repeat allele was higher in the present cohort (13%) than among
a group of healthy white women from the general population living
in Toronto, Canada (8%) (Jernstro ¨m et al, 2001b). As an extra
control group, we also performed additional IGF1 genotyping on
BRCA1-negative women belonging to the South Swedish BRCA1
families with available DNA, who did not have breast cancer at the
time of mutation testing. In total, 8.4% of the BRCA1 non-carriers
lacked the 19-repeat allele. We chose to genotype non-carriers
from the same families as the women participating in the study,
because these women belong to the same ethnic and socio-
economic background and live in the same geographic area as the
participants and are thus optimal controls. Others have reported
similar frequencies for the absence of the 19-repeat allele among
Caucasians ranging between 6.4 and 11.6% (Vaessen et al, 2001;
DeLellis et al, 2003). The absence of the IGF1 19-repeat allele was
found at a higher frequency among known BRCA1 mutation
carriers (30%) compared with other women (11.5%) in the present
study. Conversely, all women who belonged to families with
BRCA2 mutations carried at least one copy of the 19-repeat allele
in the present study. Abramovitcha et al (2003) have presented
evidence suggesting a link between the IGF-1 system and BRCA1,
and reported that the transcription of the IGF-1 receptor gene in
breast cancer-derived cell lines is under the inhibitory control of
BRCA1. Others have reported that the IGF1 genotype is linked to a
low birth weight (Arends et al, 2002) and we have previously
reported low birth weight among BRCA1 carriers compared with
non-carriers from BRCA1 families (Jernstro ¨m et al, 1998),
although no IGF-1 genotyping was performed in the latter study.
The link between the IGF-1 system and the BRCA1 gene clearly
warrants further study, and we are currently undertaking IGF1
genotyping of all BRCA1 carriers to elucidate whether the absence
of the 19-repeat allele is more frequent in mutation carriers than
non-carriers. Further studies are needed to elucidate whether the
combination of a BRCA1 mutation and lack of the 19-repeat allele
renders BRCA1 carriers especially susceptible to early-onset breast
cancer after OC exposure (Narod et al, 2002) and pregnancy
(Jernstro ¨m et al, 1999). Due to the limitation of our sample size, we
cannot exclude the possibility that other repeat lengths of the IGF1
gene are associated with breast cancer.
This is an early report from a prospective cohort of young
healthy women from high-risk breast cancer families. So far six
participants have been diagnosed with breast cancer, three with
bilateral disease. The median time of follow-up is now 1.4 years or
776 person-years. This gives an annual incidence in our cohort of
0.77%. This overall annual incidence rate is lower than in other
cohorts of high-risk women consisting of BRCA1 and BRCA2
carriers (Easton et al, 1995; Tonin et al, 1995; Ford et al, 1998).
However, the present cohort includes 53 women who are known to
not carry the respective BRCA1 or BRCA2 mutations that segregate
in their families, as well as 113 women from non-BRCA1/2 families
and 46 women from untested families. Four of the six cases are
known BRCA1 mutation carriers, while two cases were untested,
and we cannot exclude the possibility that they also carry BRCA1
or BRCA2 mutations. None of the six cases shared any familial
relationship as far as we know. In general, we have extended the
pedigrees as far back as possible, that is, usually two to four
generations; in several cases, Swedish Registry Data have been
used to confirm distant relatives. In addition to the two women
whose cancers were detected during prophylactic mastectomy, 14
other women also reported to have undergone the procedure.
These operations are self-reported and it is possible that other
women have undergone the operation without notifying us.
However, given that high-risk women undergo annual clinical
examinations, it is unlikely that we missed more than one or two
mastectomies, if any.
It would have been optimal if we had had mutation status on all
participants in the study. However, in Sweden, BRCA1/2 mutation
testing is not normally performed on women younger than 25
years of age, unless a family member has developed breast cancer
prior to age 30 years. The risk of developing breast cancer prior to
25 is considered very low even for mutation carriers. We included
women as young as 18 years old in the study and they must
decide for themselves whether they want to get tested when
they turn 25. Several of the untested women have chosen to be
tested after inclusion in the study, but quite a few of the youngest
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swomen are still untested. For women belonging to untested
families, we are unable to test the women until a family member
with breast or ovarian cancer agrees to get tested. The two women
from untested families who themselves got breast cancer have
chosen to not undergo mutation testing at this point and we are
prohibited by Swedish law to perform mutation testing against
somebody’s will.
In our study, the body-weight-adjusted breast volumes were
larger in parous than in nulliparous women and in hormonal
contraceptive users lacking the 19-repeat allele than in non-users,
while the opposite was true for women carrying at least one copy
of the 19-repeat allele and the interaction was highly significant.
This suggests a differential response in the breast tissue to both
pregnancy and exogenous hormone exposure depending on IGF1
genotype. It also suggests increased breast epithelial proliferation
after pregnancy, resulting in permanently larger breast volumes in
women lacking the 19-repeat allele. Insulin-like growth factor-1
stimulates cell proliferation and reduces cell apoptosis (LeRoith
and Roberts, 2003) and is associated with breast volume
(Jernstro ¨m and Olsson, 1997; Hartmann et al, 1998). Dupont and
Page reported a higher risk of breast cancer with larger breast
volumes, but only in women with proliferative breast disease
(Dupont and Page, 1987). Conversely, Thurfjell et al (1996)
reported small breast sizes to be associated with increasing breast
risk through their association with high-risk parenchymal pattern
among Swedish women undergoing mammography. However,
Egan et al (1999) reported that only larger breast sizes in lean
women prior to the first full-term pregnancy were associated with
increased risk of breast cancer, and commented that studies that
lacked an associated between breast size and breast cancer did not
consider the effect modification by overall obesity. A full-term
pregnancy is associated with lower levels of IGF-1 in the general
population (Holmes et al, 2002), although it is unknown whether
this also pertains to women with no copy of the 19-repeat allele. In
the present study of high-risk women, we did not observe lower
levels of IGF-1 in parous compared with nulliparous women
irrespective of IGF1 genotype, which is in contrast to the previous
report (Holmes et al, 2002). Furthermore, each pregnancy up to
three is associated with an increased risk of early breast cancer
among BRCA1 and BRCA2 carriers (Jernstro ¨m et al, 1999) and it is
possible that this is partly mediated through the IGF-1 pathway.
Based on our observation of a statistically significant interaction
between parity and IGF1 genotype on body-weight-adjusted breast
volume, it is possible that this gene could be a marker of women at
higher risk for pregnancy-associated breast cancers. Insulin-like
growth factor-1 is one of the key growth factors in breast epithelial
development (Hovey et al, 2002). We have previously reported an
association between breast volume and IGF-1 levels in nulliparous
women not using OCs (Jernstro ¨m and Olsson, 1997). Hartmann
et al (1998) have reported that only young women who responded
with a significant increase in IGF-1 levels when they underwent
hormonal breast augmentation with oestrogen demonstrated
substantial increases in their breast volumes. The IGF1 genotype
was not analysed in that study. It would be optimal if we could
measure breast sizes and IGF-1 levels before and after OC use and
pregnancies in a large population-based cohort of women with
known IGF1 genotype to confirm whether the response to
hormone exposure is dependent on the IGF1 genotype. To our
knowledge, the present study is the first to explore the association
between IGF1 genotype and breast volume.
There is no standard way of measuring breast volume. In this
study, breast volume was measured and approximated to a
pyramid for practical reasons. We have previously published data
on breast volume measured by the same technique as in the present
study in relation to exogenous and endogenous hormone exposure
among 19–25-year-old healthy nulliparous women (Jernstro ¨ma n d
Olsson, 1997). The correlation between the measurements taken on
cycle days 5–10 and 18–23 was high in the present study (rs¼0.98;
Po0.0001). Using brassiere cup size as a measurement of breast
volume is a less satisfactory method, since different brands of
brassieres differ in size. Furthermore, an increase in rib cage
circumference results in a decrease in cup size. Thus, for two women
with the same breast volume but different rib cage circumferences,
the woman with the narrower rib cage would wear a larger cup size
than the one with the wider rib cage. A more exact procedure may
have been to use water displacement, which we actually tried, but it
ended up being very messy and was actually less reproducible than
the approximated pyramid. We only have breast measurements
taken either before or after pregnancy, and serial measurements in
each woman to confirm an actual increase or decrease in breast
volume depending on IGF1 genotype would have been preferable.
Mammography or ultrasound would have allowed us to validate the
amount of breast epithelium of each woman. However, because
many women in our study were very young, not all of them have
undergone mammography or ultrasound.
The main findings of this prospective study were that the
absence of the IGF1 19-repeat allele was associated with larger
breast volumes in parous women and hormonal contraceptive
users and an idiosyncratic response to hormonal contraceptives
among nulliparous women. An early analysis of new breast cancers
in the cohort also supported our hypothesis that absence of the 19-
repeat allele in combination with hormonal contraceptives may be
associated with an increased risk of early-onset breast cancer. The
absence of the IGF1 19-repeat allele may be a new biomarker of
increased OC- and pregnancy-associated breast cancer, especially
among BRCA mutation carriers where early-onset breast cancer is
common. To our knowledge, this is the first time the effect of the
IGF1 genotype in combination with teenage OC use on early-onset
breast cancer incidence has been explored. Our data are strong
enough to tolerate up to four additional cases that all carry the
common IGF1 19-repeat allele instead of the high-risk genotype,
that is, absence of the 19-repeat allele, and still remain significant.
However, this is an early report and whether the absence of the
IGF1 19-repeat allele could be used as an additional marker to
improve risk estimates for early-onset breast cancer during genetic
counselling warrants confirmation in a larger cohort.
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